Compass Therapeutics, Inc. (CMPX)

NASDAQ: CMPX · IEX Real-Time Price · USD
1.980
-0.070 (-3.41%)
At close: Mar 28, 2024, 4:00 PM
2.130
+0.150 (7.58%)
After-hours: Mar 28, 2024, 6:00 PM EDT

Company Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States.

The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies.

The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics, Inc.
Compass Therapeutics logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 32
CEO Dr. Vered Bisker-Leib M.D., MBA, Ph.D.

Contact Details

Address:
80 Guest Street
Boston, Massachusetts 02135
United States
Phone 617-500-8099
Website compasstherapeutics.com

Stock Details

Ticker Symbol CMPX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001738021
CUSIP Number 20454B104
ISIN Number US20454B1044
SIC Code 2836

Key Executives

Name Position
Dr. Vered Bisker-Leib M.D., MBA, Ph.D. Chief Executive Officer
Dr. Thomas J. Schuetz M.D., Ph.D. Co-Founder, President of Research and Development and Vice Chair
Neil L. Lerner CPA Vice President of Finance
Jonathan Anderman J.D. Vice President, Head of Legal and Corporate Secretary
Anna Gifford Communications Manager
Dr. Minori Rosales M.D., Ph.D. Senior Vice President and Head of Clinical Development
Karin Herrera B.A. Vice President and Head of Clinical Operations
Dr. James Kranz Ph.D. Vice President and Head of Chemistry Manufacturing and Controls

Latest SEC Filings

Date Type Title
Mar 22, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 21, 2024 10-K Annual Report
Mar 21, 2024 8-K Current Report
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 1, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 9, 2024 8-K Current Report
Jan 5, 2024 8-K Current Report
Nov 27, 2023 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 9, 2023 10-Q Quarterly Report